series-c-plus
Stage
2015
Founded
3
Investors
About
Karuna Therapeutics is a biopharmaceutical company developing therapies for neuropsychiatric disorders; its lead product KarXT (marketed as Cobenfy) is an FDA-approved muscarinic receptor-targeting treatment for schizophrenia in adults.
Explore Karuna Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.